Abbott Laboratories
ABTWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $104.48 (close on November 18) and with the other assumptions at their starting point, Abbott Laboratories's sales would need to grow 13.3% a year for ten years; over its last decade, the median was 5.1%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 20,405 | — | 15.5% |
| 12/2016 | 20,853 | 2.2% | 16.0% |
| 12/2017 | 27,390 | 31.3% | 7.2% |
| 12/2018 | 30,578 | 11.6% | 13.5% |
| 12/2019 | 31,904 | 4.3% | 15.8% |
| 12/2020 | 34,608 | 8.5% | 17.1% |
| 12/2021 | 43,075 | 24.5% | 21.0% |
| 12/2022 | 43,653 | 1.3% | 20.7% |
| 12/2023 | 40,109 | −8.1% | 17.8% |
| 12/2024 | 41,950 | 4.6% | 17.9% |
| 12/2025 | 44,328 | 5.7% | 19.7% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Abbott Laboratories files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 4.6% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 17.9% of sales.
- Working capital needed to grow: $6.7 per $100 of new sales.
- Capital spending: 4.9% of sales.
- Stock pay to employees: 2.3% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- Its share price moves less than the market: a five-year beta of 0.45; the median is 0.94.
- Over ten years, its worst fall from a high was 42%; the median is 56%.
- It is one of the big ones: it sells $44.3 billion a year; the median of grinboss companies is $15.1 billion.
- It sold more than the year before in 9 of the last 10 years.
Against
- Its net debt equals 2.4 years of operating profit plus depreciation and amortization (EBITDA), more than the median (1.5).
- Its capital spending takes 4.9% of its sales every year, more than the median (3.3%).
- It ties up $7 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
- Its stock pay to employees comes to 2.3% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
Next results: January 28, 2027.
Other companies in its sector (Health Care)
Align Technology (ALGN) · Alnylam Pharmaceuticals (ALNY) · Amgen (AMGN) · Baxter International (BAX) · Becton Dickinson (BDX) · Biogen (BIIB) · Bristol Myers Squibb (BMY) · Boston Scientific (BSX) · All companies
Loading the model…